Capmatinib for the treatment of non-small cell lung cancer.

: Activation of the MET pathway through amplifications or mutations is present in 3-4% of stage IV non-squamous non-small cell lung cancers (NSCLC). High amplifications and exon 14 skipping mutations are associated with poor prognosis: new treatments are needed for these patients. Capmatinib is a highly selective, potent small-molecule MET inhibitor with antitumor activity in NSCLC and . : This article provides an overview of the capmatinib clinical development program in NSCLC, both as monotherapy in NSCLC with a dysregulated MET pathway, and in combination with epidermal growth factor receptor (EGFR) inhibitor therapy in -mutant NSCLC with MET-based acquired resistance to previous EGFR inhibition. : In the GEOMETRY Mono-1 study, treatment with capmatinib resulted in high response rates in stage IV NSCLC with exon 14 skipping mutations, particularly in first line, supporting testing for this biomarker at the time of diagnosis. Durable responses have been reported and results in -amplified NSCLC are eagerly anticipated. In -mutant NSCLC, notable responses have been observed in combination with an EGFR-tyrosine kinase inhibitor (TKI) in case of acquired resistance to EGFR-TKIs based on high amplification.